<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012234611
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEULASTIM 6MG-0.6ML PRE-FILLED SYRINGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGFILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2568.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            KYOWA KIRIN LIMITED 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neulastim contains the active substance pegfilgrastim. Pegfilgrastim is a protein produced by biotechnology in bacteria called <em>E. coli</em>.&nbsp; It belongs to a group of proteins called cytokines, and is very similar to a natural protein (granulocyte-colony stimulating factor) produced by your own body.</p><p>&nbsp;</p><p>Neulastim is used to reduce the duration of neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever) which can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells).&nbsp; White blood cells are important as they help your body fight infection.&nbsp; These cells are very sensitive to the effects of chemotherapy which can cause the number of these cells in your body to decrease.&nbsp; If white blood cells fall to a low level there may not be enough left in the body to fight bacteria and you may have an increased risk of infection.</p><p>&nbsp;</p><p>Your doctor has given you Neulastim to encourage your bone marrow (part of the bone which makes blood cells) to produce more white blood cells that help your body fight infection.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Neulastim</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pegfilgrastim, filgrastim, <em>E. coli </em>derived proteins, or any of the other ingredients of this medicine.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Neulastim:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), redness and flushing, skin rash and areas of the skin that itch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an allergy to latex. &nbsp;The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a cough, fever and difficulty breathing. &nbsp;This can be a sign of Acute Respiratory Distress Syndrome (ARDS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any of the following or combination of the following side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness</p><p>These could be symptoms of condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body. &nbsp;See section&nbsp;4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get left upper abdominal pain or pain at the tip of your shoulder. &nbsp;This may be a sign of a problem with your spleen (splenomegaly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a serious lung infection (pneumonia), fluid in the lungs (pulmonary oedema), inflammation of the lungs (interstitial lung disease) or an abnormal chest x-ray (lung infiltration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are aware of any altered blood cell counts (e.g. increase in white blood cells or anaemia) or decreased blood platelet counts, which reduces the ability of your blood to clot (thrombocytopenia). &nbsp;Your doctor may want to monitor you more closely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have sickle cell anaemia. &nbsp;Your doctor may monitor your condition more closely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a patient with breast cancer or lung cancer, Neulastim in combination with chemotherapy and/or radiation therapy may increase your risk of a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukaemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing these could be signs of a severe allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have symptoms of inflammation of aorta (the large blood vessel which transports blood from the heart to the body), this has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience those symptoms.</p><p>&nbsp;</p><p>Your doctor will check your blood and urine regularly as Neulastim can harm the tiny filters inside your kidneys (glomerulonephritis).</p><p>&nbsp;</p><p>Severe skin reactions (Stevens-Johnson syndrome) have been reported with the use of Neulastim. Stop</p><p>using Neulastim and seek medical attention immediately if you notice any of the symptoms described in section 4.</p><p>&nbsp;</p><p>You should talk to your doctor about your risks of developing cancers of the blood. &nbsp;If you develop or are likely to develop cancers of the blood, you should not use Neulastim, unless instructed by your doctor.</p><p>&nbsp;</p><p><strong>Loss of response to pegfilgrastim</strong></p><p>&nbsp;</p><p>If you experience a loss of response or failure to maintain a response with pegfilgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise pegfilgrastim&rsquo;s activity.</p><p>&nbsp;</p><p>Other medicines and Neulastim</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.&nbsp; Neulastim has not been tested in pregnant women.&nbsp; It is important to tell your doctor if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; think you may be pregnant; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are planning to have a baby.</p><p>&nbsp;</p><p>Unless your doctor directs you otherwise, you must stop breast feeding if you use Neulastim.</p><p><strong>&nbsp;</strong></p><p><strong>Driving</strong> <strong>and</strong> <strong>using</strong> <strong>machines</strong></p><p>&nbsp;</p><p>Neulastim has no or negligible effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Neulastim contains sorbitol (E420) and sodium </strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains 30&nbsp;mg sorbitol in each pre-filled syringe which is equivalent to 50&nbsp;mg/mL.</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 6&nbsp;mg dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neulastim is for use in adults aged 18 and over.</p><p>&nbsp;</p><p>Always take Neulastim exactly as your doctor has told you.&nbsp; You should check with your doctor or pharmacist if you are unsure.&nbsp; The usual dose is one 6&nbsp;mg subcutaneous injection (injection under your skin) using a pre-filled syringe and it should be given at least 24 hours after your last dose of chemotherapy at the end of each chemotherapy cycle.</p><p>&nbsp;</p><p><strong>Injecting Neulastim yourself</strong></p><p><strong>&nbsp;</strong></p><p>Your doctor may decide that it would be more convenient for you to inject Neulastim yourself.&nbsp; Your doctor or nurse will show you how to inject yourself.&nbsp; Do not try to inject yourself if you have not been trained.</p><p>&nbsp;</p><p>For further instructions on how to inject yourself with Neulastim, please read the section at the end of this leaflet.</p><p>&nbsp;</p><p>Do not shake Neulastim vigorously as this may affect its activity.</p><p>&nbsp;</p><p>If you use more Neulastim than you should</p><p>&nbsp;</p><p>If you use more Neulastim than you should contact your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>If you forget to inject Neulastim</p><p>&nbsp;</p><p>If you have forgotten a dose of Neulastim, you should contact your doctor to discuss when you should inject the next dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Please tell your doctor immediately if you have any of the following or combination of the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. &nbsp;These symptoms generally develop in a rapid fashion.</p><p>&nbsp;</p><p>These could be symptoms of an uncommon (may affect up to 1 in 100 people) condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain.&nbsp; Your doctor will tell you what you can take to ease the bone pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and headaches.</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general aches and pains in the joints and muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some changes may occur in your blood, but these will be detected by routine blood tests. &nbsp;Your white blood cell count may become high for a short period of time. &nbsp;Your platelet count may become low which might result in bruising.</p><p>&nbsp;</p><p><strong>Uncommon</strong><strong> side effects </strong>(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic-type reactions, including redness and flushing, skin rash, and raised areas of the skin that itch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reactions, including anaphylaxis (weakness, drop in blood pressure, difficulty breathing, swelling of the face).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased spleen size.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spleen rupture.&nbsp; Some cases of splenic rupture were fatal. &nbsp;It is important that you contact your doctor immediately if you experience pain in the upper left side of the abdomen or left shoulder pain since this may relate to a problem with your spleen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems. &nbsp;If you have a cough, fever and difficulty breathing please tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sweet&rsquo;s syndrome (plum-coloured, raised, painful lesions on the limbs and sometimes the face and neck with fever) has occurred but other factors may play a role.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cutaneous vasculitis (inflammation of the blood vessels in the skin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the tiny filters inside your kidneys (glomerulonephritis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood (haemoptysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood disorders (myelodysplastic syndrome [MDS] or acute myeloid leukaemia [AML]).</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section 2.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the lung (pulmonary haemorrhage).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome, which can appear as reddish target-like or circular patches oftenn with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms. Stop using Neulastim if you develop these symptoms and contact your doctor or seek medical attention immediately. See also section 2.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. &nbsp;This includes any possible side effects not listed in this leaflet. &nbsp;By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the syringe label after EXP. &nbsp;The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).&nbsp;</p><p>&nbsp;</p><p>You may take Neulastim out of the refrigerator and keep it at room temperature (not above 30&deg;C) for no longer than 3 days.&nbsp; Once a syringe has been removed from the refrigerator and has reached room temperature (not above 30&deg;C) it must either be used within 3 days or disposed of.</p><p>&nbsp;</p><p>Do not freeze. &nbsp;Neulastim may be used if it is accidentally frozen for a single period of less than 24&nbsp;hours.</p><p>&nbsp;</p><p>Keep the container in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice it is cloudy or there are particles in it.&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. &nbsp;Ask your pharmacist how to throw away medicines you no longer use. &nbsp;These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Neulastim contains</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pegfilgrastim. &nbsp;Each pre-filled syringe contains 6&nbsp;mg of pegfilgrastim in 0.6&nbsp;ml of solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium acetate: 0.35mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sorbitol (E420): 30mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polysorbate 20: 0.02mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water for injection: To 0.6ml &nbsp;&nbsp;See section&nbsp;2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Neulastim looks like and contents of the pack

Neulastim is a clear, colourless solution for injection in a pre-filled syringe (6 mg/0.6 ml). 

Each pack contains 1 pre-filled syringe of type I glass with an attached stainless steel needle and needle cap.  The syringes are provided either with or without a blister wrapping.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Site of Manufacture of the Drug Product</strong></p><p>Amgen Manufacturing Limited</p><p>State Road 31</p><p>Kilometer 24.6</p><p>Juncos 00777-4060</p><p>Puerto Rico</p><p>USA</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>Kyowa Kirin Limited</p><p>Galabank Business Park</p><p>Galashiels</p><p>TD1 1QH</p><p>UK</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in November 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو نيولاستيم وماهي استخداماته</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي نيولاستيم على المادة الفعالة بيغفيلغراستيم. إن بيغفيلغراستيم هو بروتين يُنتج من خلال تكنولوجيا حيوية ببكتيريا تُسمى <em>الإشريكية القولونية</em>. تنتمي لمجموعة من البروتينات يُطلق عليها اسم السيتوكينات، وهي شديدة الشبه ببروتين طبيعي (عامل تحفيز مستعمرة الكريات البيضاء) ينتجه الجسم البشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم نيولاستيم لتقليل مدة حالة قلة العَدِلات (تعداد خلايا الدم البيضاء المنخفض) وحدوث قلة العَدِلات الحموية (تعداد خلايا الدم البيضاء المنخفض المصحوب بحمى) الذي قد يسببه استخدام العلاج الكيميائي السام للخلايا (الأدوية التي تُدمر الخلايا النامية بسرعة). تُعتبر خلايا الدم البيضاء مهمة نظرا لأنها تساعد جسمك على مكافحة العدوى. إن هذه الخلايا حساسة للغاية تجاه آثار العلاج الكيميائي الذي يمكنه التسبب في قلة عدد هذه الخلايا في جسمك. إذا انخفض عدد خلايا الدم البيضاء إلى مستوى منخفض فقد لا يتبقى عدد كاف في الجسم لمكافحة البكتيريا وقد تتعرض لخطر زائد للإصابة بالعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد أعطاك طبيبك دواء نيولاستيم ليحُث نخاع العظم الخاص بك (الجزء من العظم الذي يُنتج خلايا الدم) على إنتاج المزيد من خلايا الدم البيضاء التي تساعد جسمك على مكافحة العدوى.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المطلوب</strong><strong> </strong><strong>الإلمام</strong><strong> </strong><strong>بها</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>استخدام</strong><strong> نيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم نيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه بيغفيلغراستيم أو فيلغراستيم أو البروتينات المشتقة من <em>الإشريكية القولونية </em>أو تجاه أيٍ من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي أو الممرضة قبل استخدام نيولاستيم:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت برد فعل تحسسي بما في ذلك الإحساس بالضعف وانخفاض ضغط الدم وصعوبة التنفس وتورم الوجه (التأق) والاحمرار والبيغ والطفح الجلدي وحكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بتحسس من اللاتكس. فقد يحتوي غطاء الإبرة بالحقنة المملوءة مسبقا على مشتق من اللاتكس وقد يتسبب في تفاعلات حساسية حادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سعال وحمى وصعوبة في التنفس. قد تكون هذه علامة إصابة بمتلازمة الضائقة التنفسية الحادة (ARDS)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت بأيٍ من الآثار الجانبية التالية أو بمزيج منها:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو انتفاخ، اللذان قد يصاحبهما التبول بنسبة أقل وصعوبة التنفس وتورم البطن والشعور بالامتلاء وشعور عام بالتعب</p><p dir="RTL">قد تكون هذه أعراض حالة تُسمَّى &quot;متلازمة التسرب الشعيري&quot; والتي تسبب تسرب الدم من الأوعية الدموية الصغيرة إلى جسمك. انظر القسم ٤.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا &nbsp;قد أُصِبت بألم بالجزء العلوي الأيسر من البطن أو بألم في طرف كتفك. قد تكون هذه علامة لوجود مشكلة بطحالك (تضخم الطحال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت مؤخرا بعدوى خطيرة بالرئة (التهاب رئوي) أو بسائل في الرئتين (الوذمة الرئوية) أو بالتهاب الرئتين (داء الرئة الخلالي) أو خضعت لفحوصات أشعة سينية غير طبيعية على الصدر (الارتشاح الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على دراية بأي تغير في تعدادات خلايا الدم (على سبيل المثال، زيادة في عدد خلايا الدم البيضاء أو فقر الدم) أو بالتعدادات المنخفضة للصفائح الدموية، التي تقلل من قدرة دمك على التخثر (نقص الصفائح الدموية). قد يرغب طبيبك في مراقبتك بصورة أكثر دقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعاني من فقر الدم المنجلي&rlm;. قد يراقب طبيبك حالتك بصورة أكثر دقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا بسرطان الثدي أو الرئة، قد يزيد استخدام نيولاستيم بتوليفة مع العلاج الكيميائي و/أو العلاج الإشعاعي من خطر تعرضك للإصابة بحالة في الدم سابقة للتسرطن تعرف بمتلازمة خلل التنسج النخاعي (MDS) أو بنوع من سرطان الدم اسمه ابيضاض الدم (اللوكيميا) النخاعي الحاد (AML). وقد تشمل الأعراض الإعياء والحمى وحدوث كدمات أو نزف لأبسط الأسباب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت لعلامات حساسية (تحسس) مفاجئة مثل الطفح الجلدي أو الحكة أو شرى على الجلد أو تورم في الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم أو ضيق في التنفس أوصفير أو صعوبة في التنفس فقد تكون هذه العلامات دلائل على وجود رد فعل تحسسي شديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أعراض التهاب الشريان الأورطي (الشريان الدموي الكبير الذي ينقل الدم من القلب إلى الجسم)، وهي حالة تم الإبلاغ عن حدوثها في حالات نادرة لدى مرضى السرطان والمتطوعين الأصحاء. يمكن أن تتضمن الأعراض الحمى، وألم البطن، والتوعك، وألم الظهر، وزيادة العلامات الالتهابية. أخبر طبيبك إذا تعرضت لأي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يتابع طبيبك بانتظام حالة الدم والبول لديك لأنه من الممكن لنيولاستيم أن يضر بمرشحات صغيرة داخل الكليتين (التهاب كبيبات الكلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن ردود فعل جلدية شديدة (متلازمة ستيفنز-جونسون) عند استخدام نيولاستيم. توقف عن استخدام نيولاستيم واطلب الرعاية الطبية فورًا إذا لاحظت أيًا من الأعراض الموضحة في القسم (٤).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك التحدث مع طبيبك بشأن أخطار إصابتك بسرطانات الدم. إذا أُصِبت أو كنت معرضا للإصابة بسرطانات الدم، فيجب عليك ألا تستخدم نيولاستيم، إلا إذا نصحك طبيبك بتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فقدان ال</strong><strong>ا</strong><strong>ستجابة للعلاج ببيغفيلغراستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من فقدان الاستجابة أوعدم القدرة على الحفاظ على الاستجابة للعلاج ببيغفيلغراستيم، سوف يتحقق طبيبك من الأسباب بما في ذلك ما إذا كنت قد أنتجتَ الأجسام المضادة التي تُبطل مفعول بيغفيلغراستيم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى ونيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي، إذا كنت تتلقى، أو تلقيت مؤخرا، أو قد تتلقى أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">احرصي على استشارة طبيبك أو الصيدلي قبل تناول أي دواء. لم يتم اختبار نيولاستيم لدى النساء الحوامل. من المهم أن تخبري طبيبك إذا كنتِ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملا؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتقدين أنك حاملا؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخططين للإنجاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ إيقاف الرضاعة إذا كنتِ تستخدمين نيولاستيم، إلا إذا قام طبيبك بتوجيهك لخلاف ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة</strong> <strong>و</strong><strong>استخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">نيولاستيم له تأثير ضئيل أو منعدم على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي نيولاستيم على سوربيتول (</strong>٤٢٠<strong>E</strong><strong>) و الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على ٣٠ مجم من السوربيتول في كل محقنة معبأة مسبقًا وهو ما يعادل ٥٠ مجم/ملليلتر.</p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من ١ مليمول من الصوديوم (٢۳ مجم) بكل جرعة قدرها ٦ مجم، أيْ أنه أساسا &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية استخدام نيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصف نيولاستيم للاستخدام لدى البالغين من العمر ١۸ عاما فما أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التزم دوما بأخذ نيولاستيم وفقا للتعليمات التي أعطاها لك الطبيب. ينبغي عليك استشارة طبيبك أو الصيدلي إذا لم تكن واثقا. إن الجرعة المعتادة هي جرعة حقن واحدة تحت الجلد بمقدار٦ مجم باستخدام حقنة مملوءة مسبقا وينبغي إعطاؤها بعد ما لا يقل عن ٢٤ ساعة من تلقي جرعتك الأخيرة من العلاج الكيميائي في نهاية كل دورة علاج كيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حقْن نفسك بنيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك أنه ربما يكون من الأفضل لك أن تقوم بحقن نيولاستيم بنفسك. وسوف يوضح لك طبيبك أو الممرضة كيفية إجراء الحقن بنفسك. لا تحاول إجراء الحقن بنفسك إذا لم تكن قد تدربت على ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للمزيد من التعليمات الخاصة بكيفية حقن نفسك بنيولاستيم، يُرجى قراءة القسم الموجود في نهاية هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ترج نيولاستيم بقوة فقد يؤثر ذلك على فاعليته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدامك نيولاستيم بجرعة أكبر من اللازم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة استخدامك نيولاستيم بجرعة أكبر من اللازم، ينبغي عليك الاتصال بطبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تحقن جرعة نيولاستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد نسيت أن تتلقى إحدى جرعات نيولاستيم، ينبغي عليك الاتصال بطبيبك لتبحث معه موعد حقن الجرعة التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، يمكن لهذا الدواء التسبب في حدوث آثار جانبية، إلا أنها قد لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إخبار طبيبك على الفور إذا أُصِبت بأيٍ من الآثار الجانبية التالية أو بمزيج منها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو انتفاخ، اللذان قد يصاحبهما التبول بنسبة أقل وصعوبة التنفس وتورم البطن والشعور بالامتلاء وشعور عام بالتعب. عادة ما تتطور هذه الأعراض بصورة سريعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون هذه أعراض حالة غير شائعة )قد تُصيب الى حدود شخص واحد من بين ١٠٠) تُسمَّى &quot;متلازمة التسرب الشعيري&quot; والتي تسبب تسرب الدم من الأوعية الدموية الصغيرة إلى جسمك وهي تستدعي رعاية طبية طارئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدا </strong>(قد تُصيب أكثر من شخص واحد من بين ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام. سيُخبرك طبيبك ما الذي تستطيع أخذه لتهدئة آلام العظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة </strong>(قد تُصيب الى حدود شخص واحد من بين ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عامة وآلام بالمفاصل والعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث بعض التغييرات في دمك لكن سوف تُكتشف هذه التغييرات عبر فحوصات الدم الروتينية. قد يصبح تعداد خلايا الدم البيضاء الخاص بك عاليا لمدة فترة زمنية قصيرة. قد يصبح تعداد الصفائح الدموية الخاص بك منخفضا والذي قد ينتج عنه تكدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(قد تُصيب الى حدود شخص واحد من بين ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية بما في ذلك الاحمرار والبيغ والطفح الجلدي والمناطق المثارة بالجلد التي بها حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة، بما في ذلك التأق (احساس بالضعف وانخفاض ضغط الدم وصعوبة التنفس وتورم الوجه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حجم الطحال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الطحال. كانت بعض حالات تمزق الطحال مميتة. من المهم الاتصال بطبيبك على الفور إذا تعرضت لألم في الجانب الأيسر العلوي من معدتك أو ألم في كتفك الأيسر نظرا لأن ذلك قد يكون له علاقة بمشكلة في طحالك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس. إذا كنت مُصابا بالسعال والحمى وصعوبة في التنفس، يُرجى إخبار طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث متلازمة سويت (آفات برقوقية اللون بارزة ومؤلمة بالأطراف، تظهر أحيانا في الوجه والعنق، مصحوبة بحمى) لكن قد تلعب عوامل أخرى دورا في إحداث ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الجلدية (التهاب الأوعية الدموية في الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضرر بمرشحات صغيرة داخل الكليتين (التهاب كبيبات الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار بموقع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مقرون بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم (خلل التنسج النخاعي [<strong>MDS</strong>] أو ابيضاض الدم (اللوكيميا) النخاعي الحاد [<strong>AML</strong>]).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة (</strong>قد تُصيب الى حدود ١ من بين كل ١٠٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشريان الأورطي (الشريان الدموي الكبير الذي ينقل الدم من القلب إلى الجسم) ، انظر القسم 2.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئة (نزيف رئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز-جونسون والتي تظهر على هيئة بقع مائلة للون الأحمر مثل علامات تصويب الأهداف أو بقع دائرية، وغالبًا ما تصحبها بثور في المنتصف في منطقة الجذع، وتقشر الجلد، وقروح في الفم والحلق والأنف والأعضاء التناسلية والعينين وقد يسبقها حمى أو أعراض تشبه أعراض الأنفلونزا. توقف عن استخدام نيولاستيم إذا أصبت بهذه الأعراض واتصل بطبيبك أو اطلب الرعاية الطبية فورًا. انظر أيضًا القسم (٢).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فأخبر بها طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. بالإبلاغ عن الأعراض الجانبية يمكنك أن تساعد في توفير معلومات أكثر عن مأمونية هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدا عن مرأى و متناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الخارجية وعلى الملصق الخاص بالحقنة بعد رمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (٢&deg;م - ۸&deg;م).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك إخراج نيولاستيم من الثلاجة وتركه في درجة حرارة الغرفة (لا تتعدى۳٠م&deg;) لمدة لا تزيد عن ۳ أيام. بمجرد إخراج الحقنة من الثلاجة ووصولها لدرجة حرارة الغرفة (لا تتعدى۳٠م&deg;)، يجب استخدامها خلال ۳ أيام أو التخلص منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتم تجميده. يمكن استخدام نيولاستيم في حال تجميده بالخطأ لفترة زمنية واحدة لا تتعدى٢٤ ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ العبوة داخل العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أنه معكر أو يحتوي على جسيمات.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات نيولاستيم</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي بيغفيلغراستيم. تحتوي كل حقنة مملوءة مسبقا على ٦ مجم من بيغفيلغراستيم في ٠٫٦مل من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;أسيتات الصوديوم: ٠٫٣٥ مجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السوربيتول<strong> </strong>(٤٢٠E): ٣٠ مجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوليسوربات ٢٠ : ٠٫٠٢ مجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ماء للحقن: إلى حدود ٠٫٦ مل. انظر القسم ٢.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيولاستيم هو عبارة عن محلول صاف شفاف للحقن في حقنة مملوءة مسبقا (٦ مجم/٠٫٦ مل).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على حقنة زجاجية واحدة مملوءة مسبقا من النوع الأول مُرفق معها إبرة من الفولاذ المقاوم للصدأ وغطاء للإبرة. تأتي الحقنة مع أو دون تغليف بليستر.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موقع التصنیع الأولي</strong></p><p dir="RTL">Amgen Manufacturing Limited</p><p dir="RTL">State Road 31</p><p dir="RTL">Kilometer 24.6</p><p dir="RTL">Juncos 00777-4060</p><p dir="RTL">Puerto Rico</p><p dir="RTL">الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">&nbsp;ZK Breda4817</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">Kyowa Kirin Limited</p><p dir="RTL">Galabank Business Park</p><p dir="RTL">Galashiels</p><p dir="RTL">TD1 1QH</p><p dir="RTL">المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في  نوفمبر ٢٠ ٢٠.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neulastim 6 mg solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 ml solution for injection.  The concentration is 10 mg/ml based on protein only**.

*Produced in Escherichia coli cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG).
** The concentration is 20 mg/ml if the PEG moiety is included.

The potency of this product should not be compared to the potency of another pegylated or non pegylated protein of the same therapeutic class.  For more information, see section 5.1.

Excipient(s) with known effect: 
Each pre-filled syringe contains 30 mg sorbitol (E420) (see section 4.4).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection). 

Clear, colourless solution for injection. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Neulastim therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">One 6&nbsp;mg dose (a single pre-filled syringe) of Neulastim is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim in children has not yet been established. &nbsp;Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patients with renal impairment</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">No dose change is recommended in patients with renal impairment, including those with end stage renal disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Neulastim is injected subcutaneously.&nbsp; The injections should be given into the thigh, abdomen or upper arm.&nbsp; For instructions on handling of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Traceability </u></p><p dir="ltr">&nbsp;</p><p dir="ltr">In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with <em>de novo</em> acute myeloid leukaemia (see section 5.1).&nbsp; However, the long-term effects of Neulastim have not been established in acute myeloid leukaemia; therefore, it should be used with caution in this patient population.</p><p dir="ltr">&nbsp;</p><p dir="ltr">G-CSF can promote growth of myeloid cells <em>in vitro</em> and similar effects may be seen on some non-myeloid cells <em>in vitro</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim have not been investigated in patients with myelodysplastic syndrome, chronic myelogenous leukaemia, and in patients with secondary Acute Myeloid Leukaemia (AML); therefore, it should not be used in such patients. &nbsp;Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from acute myeloid leukaemia.&nbsp;&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim administration in <em>de novo</em> AML patients aged &lt; 55 years with cytogenetics t(15;17) have not been established.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim have not been investigated in patients receiving high dose chemotherapy. &nbsp;This medicinal product should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pulmonary adverse events</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration. &nbsp;Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil count may be preliminary signs of acute respiratory distress syndrome (ARDS). &nbsp;In such circumstances Neulastim should be discontinued at the discretion of the physician and the appropriate treatment given (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Glomerulonephritis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim.&nbsp; Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim.&nbsp; Urinalysis monitoring is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Capillary leak syndrome</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Capillary leak syndrome has been reported after G-CSF administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. &nbsp;Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Splenomegaly and splenic rupture</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon but generally asymptomatic cases of splenomegaly and uncommon cases of splenic rupture, including some fatal cases, have been reported following administration of pegfilgrastim (see section 4.8). &nbsp;Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). &nbsp;A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Thrombocytopenia and anaemia</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with Neulastim alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule. &nbsp;Regular monitoring of platelet count and haematocrit is recommended. &nbsp;Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients </u></p><p dir="ltr">&nbsp;</p><p dir="ltr">In the post-marketing observational study setting, pegfilgrastim in conjunction with chemotherapy and/or radiotherapy has been associated with development of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) in breast and lung cancer patients (see section&nbsp;4.8). Monitor breast and lung cancer patients for signs and symptoms of MDS/AML.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sickle cell anaemia</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait or sickle cell disease (see section 4.8).&nbsp; Therefore, physicians should use caution when prescribing Neulastim in patients with sickle cell trait or sickle cell disease, should monitor appropriate clinical parameters and laboratory status and be attentive to the possible association of this medicine with splenic enlargement and vaso‑occlusive crisis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Leukocytosis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">White blood cell (WBC) counts of 100&nbsp;x&nbsp;10<sup>9</sup>/l or greater have been observed in less than 1% of patients receiving Neulastim.&nbsp; No adverse events directly attributable to this degree of leukocytosis have been reported.&nbsp; Such elevation in white blood cells is transient, typically seen 24 to 48&nbsp;hours after administration and is consistent with the pharmacodynamic effects of this medicine.&nbsp; Consistent with the clinical effects and the potential for leukocytosis, a WBC count should be performed at regular intervals during therapy. &nbsp;If leukocyte counts exceed 50&nbsp;x&nbsp;10<sup>9</sup>/l after the expected nadir, this medicine should be discontinued immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Stevens-Johnson syndrome</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, has been reported rarely in association with pegfilgrastim treatment. If the patient has developed SJS with the use of pegfilgrastim, treatment with pegfilgrastim must not be restarted in this patient at any time.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hypersensitivity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with Neulastim.&nbsp; Permanently discontinue Neulastim in patients with clinically significant hypersensitivity.&nbsp; Do not administer Neulastim to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.&nbsp; If a serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow-up over several days.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Immunogenicity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">As with all therapeutic proteins, there is a potential for immunogenicity.&nbsp; Rates of generation of antibodies against pegfilgrastim is generally low.&nbsp; Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Aortitis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. The</p><p dir="ltr">symptoms experienced included fever, abdominal pain, malaise, back pain and increased inflammatory</p><p dir="ltr">markers (e.g. c-reactive protein and white blood cell count). In most cases aortitis was diagnosed by</p><p dir="ltr">CT scan and generally resolved after withdrawal of GCSF. See also section 4.8.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Other warnings</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim for the mobilisation of blood progenitor cells in patients or healthy donors has not been adequately evaluated.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The needle cap of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging findings. &nbsp;This should be considered when interpreting bone-imaging results.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sorbitol</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sodium</u></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Neulastim contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 6&nbsp;mg dose, &nbsp;that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy&sbquo; Neulastim should be administered at least 24 hours after administration of cytotoxic chemotherapy.&nbsp; In clinical trials, Neulastim has been safely administered 14 days before chemotherapy. &nbsp;Concomitant use of Neulastim with any chemotherapy agent has not been evaluated in patients. &nbsp;In animal models concomitant administration of Neulastim and 5-fluorouracil (5-FU) or other antimetabolites has been shown to potentiate myelosuppression.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Possible interactions with other haematopoietic growth factors and cytokines have not been specifically investigated in clinical trials.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated. &nbsp;There is no evidence that such an interaction would be harmful.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Neulastim have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g., nitrosoureas.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Specific interaction or metabolism studies have not been performed, however, clinical trials have not indicated an interaction of Neulastim with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There are no or limited amount of data from the use of pegfilgrastim in pregnant women.&nbsp; Studies in animals have shown reproductive toxicity (see section 5.3). &nbsp;Neulastim is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is insufficient information on the excretion of Neulastim/metabolites in human milk, a risk to the newborns/infants cannot be excluded. &nbsp;A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from Neulastim therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area) (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Neulastim has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The most frequently reported adverse reactions were bone pain (very common [&ge; 1/10]) and musculoskeletal pain (common [&ge;&nbsp;1/100 to &lt;&nbsp;1/10]).&nbsp; Bone pain was generally of mild to moderate severity, transient and could be controlled in most patients with standard analgesics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythema, flushing, and hypotension occurred on initial or subsequent treatment with Neulastim (uncommon [&ge;&nbsp;1/1,000 to &lt; 1/100]).&nbsp; Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulastim (uncommon) (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Capillary Leak Syndrome, which can be life-threatening if treatment is delayed, has been reported as uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) in cancer patients undergoing chemotherapy following administration of G-CSFs; see section 4.4 and section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Splenomegaly, generally asymptomatic, is uncommon.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Splenic rupture including some fatal cases is uncommonly reported following administration of pegfilgrastim (see section 4.4).&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon pulmonary adverse reactions including interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis have been reported. &nbsp;Uncommonly, cases have resulted in respiratory failure or Acute Respiratory Distress Syndrome (ARDS), which may be fatal (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (uncommon in sickle cell patients) (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list &nbsp;of adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The data in the table below describe adverse reactions reported from clinical trials and spontaneous reporting.&nbsp; Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:92%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common<br />(&ge;&nbsp;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common<br />(&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon<br />(&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare<br />(&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myelodysplastic syndrome<sup>1</sup></p><p>Acute myeloid leukaemia<sup>1</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p><p>Leukocytosis<sup>1</sup></p></td><td style="vertical-align:top"><p>Sickle cell anaemia with crisis<sup>2</sup>;</p><p>Splenomegaly<sup>2</sup>;</p><p>Splenic rupture<sup>2</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions;</p><p>Anaphylaxis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in uric acid</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Capillary leak syndrome<sup>1</sup></p></td><td style="vertical-align:top"><p>Aortitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute Respiratory Distress Syndrome2;</p><p>Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis)</p><p>Haemoptysis</p></td><td style="vertical-align:top"><p>Pulmonary</p><p>haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sweet&rsquo;s syndrome (acute febrile neutrophilic dermatosis)<sup>1,2</sup><strong>;</strong></p><p>Cutaneous vasculitis<sup>1,2</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson Syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Musculoskeletal pain (myalgia, arthralgia, pain in extremity, back pain, musculo-skeletal pain, neck pain)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glomerulonephritis<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p>Injection site pain</p><p>Non-cardiac chest pain</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in lactate dehydrogenase and alkaline phosphatase<sup>1</sup>;</p><p>Transient elevations in LFT&#39;s for ALT or AST<sup>1</sup></p><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr"><sup>&nbsp;</sup></p><p dir="ltr"><sup>1 </sup>See section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p dir="ltr"><sup>2 </sup>This adverse reaction was identified through post-marketing surveillance but not observed in randomised, controlled clinical trials in adults. &nbsp;The frequency category was estimated from a statistical calculation based upon 1,576 patients receiving Neulastim in nine randomised clinical trials.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon cases of Sweet&rsquo;s syndrome have been reported, although in some cases underlying haematological malignancies may play a role.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon events of cutaneous vasculitis have been reported in patients treated with Neulastim. &nbsp;The mechanism of vasculitis in patients receiving Neulastim is unknown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Injection site reactions, including injection site erythema (uncommon) as well as injection site pain (common) have occurred on initial or subsequent treatment with Neulastim.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Common (&ge; 1/100 to &lt; 1/10) cases of leukocytosis (White Blood Count [WBC] &gt; 100&nbsp;&times;&nbsp;10<sup>9</sup>/l) have been reported (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Reversible, mild to moderate elevations in uric acid and alkaline phosphatase, with no associated clinical effects, were uncommon; reversible, mild to moderate elevations in lactate dehydrogenase, with no associated clinical effects, were uncommon in patients receiving Neulastim following cytotoxic chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Nausea and headaches were very commonly observed in patients receiving chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon elevations in liver function tests (LFTs) for ALT (alanine aminotransferase) or AST (aspartate aminotransferase), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy. &nbsp;These elevations are transient and return to baseline.</p><p dir="ltr">&nbsp;</p><p dir="ltr">An increased risk of MDS/AML following treatment with Neulasta in conjunction with chemotherapy and/or radiotherapy has been observed in an epidemiological study in breast and lung cancer patients (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Common cases of thrombocytopenia have been reported.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of capillary leak syndrome have been reported in the post marketing setting with G-CSF use. &nbsp;These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The experience in children is limited. &nbsp;A higher frequency of serious adverse reactions in younger children aged 0-5 years (92%) has been observed compared to older children aged 6-11 and 12-21 years respectively (80% and 67%) and adults. &nbsp;The most common adverse reaction reported was bone pain (see sections 5.1 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reporting of suspected adverse reactions </u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. &nbsp;It allows continued monitoring of the benefit/risk balance of the medicinal product. &nbsp;Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>To report any side effect(s): </strong></p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222,&nbsp; Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>- &nbsp;Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Single doses of 300&nbsp;&micro;g/kg have been administered subcutaneously to a limited number of healthy volunteers and patients with non-small cell lung cancer without serious adverse reactions. &nbsp;The adverse events were similar to those in subjects receiving lower doses of pegfilgrastim<em>.</em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: immunostimulants, colony stimulating factor; ATC Code:&nbsp; L03AA13</p><p dir="ltr">&nbsp;</p><p dir="ltr">Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow.&nbsp; Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20&nbsp;kd polyethylene glycol (PEG) molecule.&nbsp; Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance.&nbsp; Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.&nbsp; Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function.&nbsp; As with other haematopoietic growth factors, G-CSF has shown <em>in vitro</em> stimulating properties on human endothelial cells.&nbsp; G-CSF can promote growth of myeloid cells, including malignant cells, <em>in vitro</em> and similar effects may be seen on some non-myeloid cells <em>in vitro</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In two randomised, double-blind, pivotal studies in patients with high risk stage II-IV breast cancer undergoing myelosuppressive chemotherapy consisting of doxorubicin and docetaxel, use of pegfilgrastim, as a single once per cycle dose, reduced the duration of neutropenia and the incidence of febrile neutropenia similarly to that observed with daily administrations of filgrastim (a median of 11 daily administrations). &nbsp;In the absence of growth factor support, this regimen has been reported to result in a mean duration of grade 4 neutropenia of 5 to7 days, and a 30-40% incidence of febrile neutropenia. &nbsp;In one study (n&nbsp;=&nbsp;157), which used a 6&nbsp;mg fixed dose of pegfilgrastim the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.8 days compared with 1.6 days in the filgrastim group (difference 0.23 days, 95% CI -0.15, 0.63). &nbsp;Over the entire study, the rate of febrile neutropenia was 13% of pegfilgrastim-treated patients compared with 20% of filgrastim-treated patients (difference 7%, 95% CI of -19%, 5%). &nbsp;In a second study (n&nbsp;=&nbsp;310), which used a weight-adjusted dose (100&nbsp;&mu;g/kg), the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.7 days, compared with 1.8 days in the filgrastim group (difference 0.03 days, 95% CI -0.36, 0.30). &nbsp;The overall rate of febrile neutropenia was 9% of patients treated with pegfilgrastim and 18% of patients treated with filgrastim (difference 9%, 95% CI of -16.8%,-1.1%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a placebo-controlled, double-blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimen associated with a febrile neutropenia rate of 10-20% (docetaxel 100&nbsp;mg/m<sup>2</sup> every 3 weeks for 4 cycles). &nbsp;Nine hundred and twenty-eight patients were randomised to receive either a single dose of pegfilgrastim or placebo approximately 24 hours (Day 2) after chemotherapy in each cycle. &nbsp;The incidence of febrile neutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1% versus 17%, p&nbsp;&lt;&nbsp;0.001). &nbsp;The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p&nbsp;&lt;&nbsp;0.001; and 2% versus 10%, p&nbsp;&lt;&nbsp;0.001).</p><p dir="ltr">&nbsp;</p><p dir="ltr">A small (n&nbsp;=&nbsp;83), phase II, randomised, double-blind study in patients receiving chemotherapy for <em>de novo</em> acute myeloid leukaemia compared pegfilgrastim (single dose of 6&nbsp;mg) with filgrastim, administered during induction chemotherapy. &nbsp;Median time to recovery from severe neutropenia was estimated as 22 days in both treatment groups. &nbsp;Long-term outcome was not studied (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a phase II (n&nbsp;=&nbsp;37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving 100&nbsp;&mu;g/kg pegfilgrastim following cycle 1 of vincristine, doxorubicin and cyclophosphamide (VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils &lt; 0.5&nbsp;&times;&nbsp;&nbsp;10<sup>9</sup>/L) was observed in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and 12-21 years (6 days and 3.7&nbsp;days, respectively) and adults. &nbsp;Additionally, a higher incidence of febrile neutropenia was observed in younger children aged 0-5 years (75%) compared to older children aged 6‑11 years and 12-21 years (70% and 33%, respectively) and adults (see sections 4.8 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">After a single subcutaneous dose of pegfilgrastim, the peak serum concentration of pegfilgrastim occurs at 16 to 120 hours after dosing and serum concentrations of pegfilgrastim are maintained during the period of neutropenia after myelosuppressive chemotherapy.&nbsp; The elimination of pegfilgrastim is non‑linear with respect to dose; serum clearance of pegfilgrastim decreases with increasing dose.&nbsp; Pegfilgrastim appears to be mainly eliminated by neutrophil mediated clearance, which becomes saturated at higher doses.&nbsp; Consistent with a self‑regulating clearance mechanism, the serum concentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery (see figure&nbsp;1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1.&nbsp; Profile of Median Pegfilgrastim Serum Concentration and Absolute Neutrophil Count (ANC) in Chemotherapy Treated Patients after a Single 6&nbsp;mg Injection</p><p dir="ltr">&nbsp;</p><p dir="ltr"><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="SigmaPlotGraphicObject.4"
  ShapeID="_x0000_i1025" DrawAspect="Content" ObjectID="_1748685818">
 </o:OLEObject>
</xml><![endif]--></p><p dir="ltr">&nbsp;</p><p dir="ltr">Due to the neutrophil-mediated clearance mechanism, the pharmacokinetics of pegfilgrastim is not expected to be affected by renal or hepatic impairment.&nbsp; In an open label, single dose study (n&nbsp;=&nbsp;31) various stages of renal impairment, including end-stage renal disease, had no impact on the pharmacokinetics of pegfilgrastim.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elderly </u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects (&gt; 65 years) is similar to that in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received 100&nbsp;&mu;g/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy. &nbsp;The youngest age group (0-5 years) had a higher mean exposure to pegfilgrastim (AUC) (&plusmn; Standard Deviation) (47.9 &plusmn; 22.5&nbsp;&mu;g&middot;hr/ml) than older children aged 6-11 years and 12-21 years (22.0 &plusmn; 13.1&nbsp;&mu;g&middot;hr/ml and 29.3 &plusmn; 23.2&nbsp;&mu;g&middot;hr/ml, respectively) (see section 5.1). &nbsp;With the exception of the youngest age group (0‑5 years), the mean AUC in paediatric subjects appeared similar to that for adult patients with high‑risk stage II-IV breast cancer and receiving 100&nbsp;&mu;g/kg pegfilgrastim after the completion of doxorubicin/docetaxel (see sections 4.8 and 5.1).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. &nbsp;In rat studies, it was shown that pegfilgrastim may cross the placenta. &nbsp;Studies in rats indicated that reproductive performance, fertility, oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected by pegfilgrastim given subcutaneously. &nbsp;The relevance of these findings for humans is not known.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium acetate*: 0.35mg**</p><p dir="ltr">Sorbitol (E420): 30mg**</p><p dir="ltr">Polysorbate 20: 0.02mg**</p><p dir="ltr">Water for injection: To 0.6ml</p><p dir="ltr">&nbsp;</p><p dir="ltr">*Sodium acetate is formed by titrating glacial acetic acid with sodium hydroxide.</p><p dir="ltr">**Based on deliverable volume of 0.6ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product must not be mixed with other medicinal products, particularly with sodium chloride solutions.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neulastim may be exposed to room temperature (not above 30&deg;C) for a maximum single period of up to 72&nbsp;hours.&nbsp; Neulastim left at room temperature for more than 72 hours should be discarded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not freeze. &nbsp;Accidental exposure to freezing temperatures for a single period of less than 24 hours does not adversely affect the stability of Neulastim.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Keep the container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pre-filled syringe (Type I glass), with a rubber stopper and a stainless steel needle.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The needle cap of the pre-filled syringe contains dry natural rubber (a derivative of latex) (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Each pre‑filled syringe contains 0.6&nbsp;ml of solution for injection. &nbsp;Pack size of one pre-filled syringe, in either a blistered or non-blistered packaging.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Before administration, Neulastim solution should be inspected visually for particulate matter.&nbsp; Only a solution that is clear and colourless should be injected.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Allow the pre-filled syringe for manual administration for automatic administration to come to room temperature for 30&nbsp;minutes before using the syringe.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Kyowa Kirin Limited
	Galabank Business Park
	Galashiels
	TD1 1QH
	UK

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of first authorisation: 22 August 2002
Date of latest renewal: 16 July 2007

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>